Tech Company Financing Transactions
HBM Alpha Therapeutics Funding Round
On 1/26/2023, HBM Alpha Therapeutics raised Seed investment from Harbour BioMed.
Transaction Overview
Company Name
Announced On
1/26/2023
Transaction Type
Venture Equity
Amount
Unknown
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to advance its leading programs, novel antibody therapies to treat congenital adrenal hyperplasia and polycystic ovary syndrome, with the lead candidate currently in IND-enabling stage.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Undisclosed, DE Undisclosed
USA
Undisclosed, DE Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Overview
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Jingsong Wang
Browse more venture capital transactions:
Prev: 1/26/2023: Welcome to the Jungle venture capital transaction
Next: 1/26/2023: PlanetWatch venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to document every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs